Verastem, Inc.

Verastem is a biopharmaceutical company that develops and commercializes targeted cancer therapeutics directed at the RAS/MAPK signaling pathway. The company's primary commercial offering is AVMAPKI FAKZYNJA CO-PACK, an oral combination of avutometinib and defactinib. Its clinical development pipeline also features VS-7375, an oral inhibitor under evaluation for solid tumors such as pancreatic, non-small cell lung, and colorectal cancers. Verastem provides its therapies to adult patients diagnosed with recurrent low-grade serous ovarian cancer following prior systemic treatment, serving healthcare providers, academic medical institutions, and community oncology practices through specialized distributors and pharmacies.

Commercial sales are concentrated in the United States, where the business distributes treatments through specialty pharmacies and distributors. Clinical research operations involve patients and investigative sites across multiple international territories, including the United States, Australia, Canada, Europe, the United Kingdom, and Japan, alongside collaboration activities in China. The provided text does not disclose the location of the company's headquarters.

Summary of the business section of Verastem's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 102 full time equivalent employees, including a total of 23 employees with M.D.”